Company Filing History:
Years Active: 1999-2011
Title: **Gang An: Pioneering Innovations in Prostate Cancer Diagnosis and Management**
Introduction
Gang An is a remarkable inventor based in Oklahoma City, OK. He has made significant contributions to the field of cancer research, specifically in the diagnosis and treatment of prostate cancer. With a total of nine patents to his name, An's work demonstrates a commitment to advancing medical technology and improving patient outcomes.
Latest Patents
Among his latest innovations, Gang An has developed a patent for a prostate-specific gene, known as UC41, which plays a crucial role in the diagnosis, prognosis, and management of prostate cancer. This invention includes detailed nucleic acid and amino acid sequences encoded by the UC41 gene, and it introduces diagnostic techniques that utilize these sequences for the detection of human prostate cancer. Additionally, the patent describes methods for treatment using antisense constructs or antibodies that are specific for UC41 gene products.
Another significant patent addresses the diagnosis of disease states through mRNA profiles in peripheral leukocytes. This invention outlines diagnostic techniques that identify RNA species present in the peripheral blood of individuals affected by certain disease states, including prostate and breast cancer, compared to healthy individuals. The methods described also evaluate protein species that show differential expression in the context of these diseases.
Career Highlights
Gang An has an impressive track record working with notable companies in the healthcare sector, including Urocor, Inc. and Laboratory Corporation of America Holdings. His experience in these organizations has allowed him to collaborate with top professionals in the field and contribute to groundbreaking advancements in cancer research.
Collaborations
Throughout his career, Gang An has collaborated with distinguished colleagues such as Robert W. Veltri and S. Mark O'Hara. These collaborations have led to the development of innovative diagnostic techniques and therapeutic approaches that continue to shape the future of cancer treatment.
Conclusion
Gang An's contributions to the field of cancer diagnosis and treatment, particularly through his patents on the UC41 gene and mRNA profiling techniques, highlight his role as a key innovator in medical research. His work not only pushes the boundaries of scientific understanding but also offers hope for improved outcomes in prostate cancer management and beyond.